As part of its scientific strategy, the Foundation ARC aims to accelerate the safe deployment of immunotherapies throughout France, for more indications and more patients. In addition to its SIGN’IT calls for projects, the Foundation ARC is organising its second ‘Signatures in Cancer Immunotherapy’ symposium, which will be held on 20 May 2026 in Paris.
The Foundation ARC is dedicated to driving forward the safe, large-scale implementation of cancer immunotherapies, with the ambition of extending their benefits to a wider spectrum of cancer indications and to a greater number of patients. To support this mission, the Foundation ARC actively mobilizes leading French scientific expertise around high-impact, ambitious, and innovative research projects aimed at identifying and validating robust predictive and prognostic signatures of response to immunotherapies.
In 2018, the Foundation ARC has launched its thematic call for proposals, “SIGN’IT – Signatures in Immunotherapy”. This flagship program has then become a cornerstone of the national research landscape, enabling the support of 61 cutting-edge projects to date, with a total investment approaching €33 million.
Building on this momentum, the Foundation ARC is proud to organize the 2nd SIGN’IT Symposium – Signatures in Cancer Immunotherapy, to be held on May 20th 2026 in Paris. This high-level scientific event will bring together SIGN’IT grant recipients and leaders in the field to present and discuss the latest advances arising from the funded projects. Designed as a forum for scientific exchange and interdisciplinary dialogue, the symposium will highlight emerging concepts, innovative methodologies, and translational breakthroughs in immunotherapy research.
The symposium is open to the national and international scientific and medical community engaged in cancer immunotherapy, and aims to foster collaborations, stimulate innovation, and accelerate the translation of biomarker research into clinical practice.
